GMP, the SOCIMI owned by the Montoro family and the Singaporean fund GIC, is finalising the purchase of AstraZeneca’s Madrid headquarters, a building located at 21–23 Calle Puerto Somport, in the Las Tablas area of Madrid, according to Expansión.
The deal has not yet been finalised, although talks are progressing well and could be concluded in the coming weeks. The asset is valued at around €100 million, according to sources familiar with the negotiations.
The asset is a building developed by Tishman Speyer and Metrovacesa in Madrid. These companies formed a joint venture in 2018 to develop offices on undeveloped land that the developer owned in Madrid’s northern business district. Designed by architects KPF and BOD, the building comprises 20,000 sqm of Grade A office space with green areas.
AstraZeneca moved its corporate headquarters to this building in 2024, after signing a lease for 5,200 sqm. Until then, the pharmaceutical company had its headquarters at the Parque Norte Business Centre, between the M-30 and Arturo Soria. In addition to AstraZeneca Spain’s offices, Madrid is home to AstraZeneca’s Healthcare Innovation Hub, a space designed to drive the transformation of the healthcare sector both in Spain and globally.
With this deal, GMP would strengthen its portfolio, which, at the end of 2025, was valued at €2.47 billion. Its portfolio includes well-located buildings in Madrid such as Castellana 77, Castellana 81, Alcalá 16, Génova 27, Titán 8, Orense 34 and Eloy Gonzalo 10. A highlight of its portfolio in Barcelona is the MILE Campus, comprising three buildings situated in the heart of Barcelona’s 22@ district.
In addition to offices, the SOCIMI has in recent months turned its attention to flexible apartments. To lead Truliving, GMP’s flexible and temporary accommodation offering in Madrid, the SOCIMI brought Jaime Monjo on board last year.
